The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery

Journal of Urology

Volumn 187, Issue 5, 2012, Pages 1548-1554

  Rini, Brian I ^a   Garcia, Jorge ^a   Elson, Paul ^a   Wood, Laura ^a   Shah, Shetal ^a   Stephenson, Andrew ^a   Salem, Mohammed ^a   Gong, Michael ^a   Fergany, Amr ^a   Rabets, John ^a   Kaouk, Jihad ^a   Krishnamurthi, Venkatesh ^a   Klein, Eric ^a   Dreicer, Robert ^a   Campbell, Steven ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

carcinoma; neoadjuvant therapy; preoperative period; renal cell; sunitinib; tumor burden

Indexed keywords

SUNITINIB;

ADULT; AGED; ARTICLE; CANCER SIZE; CANCER SURGERY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HISTOPATHOLOGY; HUMAN; KIDNEY CARCINOMA; MALE; METASTASIS; NEPHRECTOMY; PHASE 2 CLINICAL TRIAL; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEPHRECTOMY; PYRROLES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84863411111     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2011.12.075     Document Type: Article

References (17)

1. A. Bex, S. Horenblas, W. Meinhardt The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ Eur Urol 42 2002 570
2. J.R. Wagner, M.M. Walther, W.M. Linehan Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place J Urol 162 1999 43
3. A.A. Thomas, B.I. Rini, B.R. Lane Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma J Urol 181 2009 518
4. A.A. van der Veldt, M.R. Meijerink, A.J. van den Eertwegh Sunitinib for treatment of advanced renal cell cancer: primary tumor response Clin Cancer Res 14 2008 2431
5. C. Seidel, M. Fenner, A.S. Merseburger Response of renal lesions during systemic treatment with sunitinib in patients with metastatic renal cell carcinoma: a single center experience with 14 patients World J Urol 29 2011 355
6. A. Bex, A.A. van der Veldt, C. Blank Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery World J Urol 27 2009 533
7. P. Therasse, S.G. Arbuck, E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205
8. A. Kutikov, R.G. Uzzo The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth J Urol 182 2009 844
9. R.J. Motzer, J. Bacik, B.A. Murphy Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma J Clin Oncol 20 2002 289
10. D.Y. Heng, W. Xie, M.M. Regan Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study J Clin Oncol 27 2009 5794
11. N.J. Hellenthal, W. Underwood, R. Penetrante Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma J Urol 184 2010 859
12. T. Powles, I. Kayani, C. Blank The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer Ann Oncol 22 2011 1041
13. B.E. Houk, C.L. Bello, D. Kang A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients Clin Cancer Res 15 2009 2497
14. B. Shuch, S.B. Riggs, J.C. LaRochelle Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm BJU Int 102 2008 692
15. P.I. Karakiewicz, N. Suardi, C. Jeldres Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi Eur Urol 53 2008 845
16. N.G. Cost, S.E. Delacroix Jr, J.P. Sleeper The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus Eur Urol 59 2011 912
17. M.E. Salem, S.N. Shah, L.S. Wood Contrast enhanced CT (CE-CT) changes and nephrometry down-scoring of unresectable primary renal cell carcinoma (RCC) tumors in patients (Pts) treated with neoadjuvant sunitinib J Clin Oncol 29 2011 abstract 299